New LifeVantage Research Explores How Protandim® Nrf2 Supports Cellular Defense Against Five Modern Environmental Toxins*

SALT LAKE CITY, Oct. 29, 2026 (GLOBE NEWSWIRE) -- LifeVantage Corporation® (Nasdaq: LFVN) continues to lead the next generation of healthy aging with its latest in vitro research study examining how five modern environmental toxins—pollution, microplastics, ultra-processed foods, hormone disruptors, and pesticides—affect cells and the role Protandim® Nrf2 can play in helping protect against their impact. † These findings further reinforce LifeVantage's position as a pioneer in nutrigenomics and the science behind its products that ignite the human body's natural defense systems.

GlobeNewsWire • 4 hours ago

LifeVantage to Announce First Quarter Fiscal Year 2027 Results on November 9, 2026

SALT LAKE CITY, Oct. 26, 2026 (GLOBE NEWSWIRE) -- LifeVantage Corporation (Nasdaq:LFVN) a leading health and wellness company with products designed to activate optimal health processes at the cellular level, today announced that it will release financial results for its first quarter ended September 30, 2026, after the stock market closes on Monday, November 9, 2026. The Company will hold a conference call for investors at 2:30 p.m. Mountain Time (4:30 p.m. Eastern Time) that same day.

GlobeNewsWire • Oct 26, 2026

New Strong Sell Stocks for October 19th

CWH, LFVN and CGAU have been added to the Zacks Rank #5 (Strong Sell) List on October 19, 2026.

Zacks Investment Research • Oct 19, 2026

LifeVantage Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SALT LAKE CITY, Oct. 12, 2026 (GLOBE NEWSWIRE) -- LifeVantage Corporation (Nasdaq: LFVN) (“LifeVantage” or the “Company”) today announced that its Board of Directors granted inducement awards to Terrence Moorehead, the Company's President and Chief Executive Officer, under the Company's 2026 New Employee Long-Term Incentive Plan. The awards were granted pursuant to the key executive benefits agreement between the Company and Mr. Moorehead, dated as of April 15, 2026, as an inducement material to Mr. Moorehead's employment in accordance with Nasdaq Listing Rule 5635(c)(4).

GlobeNewsWire • Oct 12, 2026

LifeVantage Unveils Turnaround Plan to Rebuild Brand, Margins and Growth

Lifevantage NASDAQ: LFVN executives outlined a turnaround plan centered on strengthening the company's brand, improving consumer relevance and increasing operating efficiency during a Water Tower Research conference discussion.

MarketBeat • Sep 24, 2026

LifeVantage to Participate in the WTR Virtual Insights Conference on Wednesday, September 23, 2026

SALT LAKE CITY, Sept. 18, 2026 (GLOBE NEWSWIRE) -- LifeVantage Corporation (Nasdaq: LFVN), a leading health and wellness company with products designed to activate optimal health processes at the cellular level, today announced that Terrence Moorehead, Chief Executive Officer, and Carl Aure, Chief Financial Officer, will participate in the upcoming WTR Virtual Insights Conference on Wednesday, September 23, 2026.

GlobeNewsWire • Sep 18, 2026

Lifevantage Q4 Earnings Call Highlights

Lifevantage NASDAQ: LFVN reported lower fourth-quarter and fiscal 2026 results as the health and wellness company faced fewer orders, lower average order sizes and a difficult comparison against prior-year sales of its MindBody GLP-1 System.

MarketBeat • Aug 27, 2026

LifeVantage Corporation (LFVN) Q4 2026 Earnings Call Transcript

LifeVantage Corporation (LFVN) Q4 2026 Earnings Call Transcript

Seeking Alpha • Aug 27, 2026

LifeVantage Announces Financial Results for the Fourth Fiscal Quarter and Full Fiscal Year 2026

SALT LAKE CITY, Aug. 27, 2026 (GLOBE NEWSWIRE) -- LifeVantage Corporation (Nasdaq: LFVN), a leading health and wellness company with products designed to activate optimal health processes at the cellular level, today reported financial results for its fourth fiscal quarter ended June 30, 2026.

GlobeNewsWire • Aug 27, 2026

LifeVantage Declares Quarterly Dividend

SALT LAKE CITY, Aug. 21, 2026 (GLOBE NEWSWIRE) -- LifeVantage Corporation (Nasdaq:LFVN), a leading health and wellness company with products designed to activate optimal health processes at the cellular level, today announced that the Company's Board of Directors has approved a quarterly cash dividend of $0.050 per share of common stock, which will be paid September 15, 2026 to all stockholders of record at the close of business on September 1, 2026.

GlobeNewsWire • Aug 21, 2026